肥満関連因子を測定するELISAキット エネルギー代謝と体重調節関連因子ELISAキットシリーズ

• 競合法とサンドイッチ法ELISAキット製品例
• 製品ラインナップ
• 使用文献：Obesitology Publications

競合法とサンドイッチ法ELISAキット製品例

品名	Human Adiponectin ELISA Kit
	Competitive	High Sensitivity (Sandwich)
測定原理	競合法	サンドイッチ法
商品コード	RD195023100	RD191023100
検量線

目次に戻る

製品ラインナップ

A

C

F

I

L

M

O

P

R

S

T

V

	測定物質		測定動物種	測定試料	測定範囲	商品コード
A	Adipocyte FABP		Human	S, P	0.5～25 ng/ml	RD191036200R
	Adiponectin	(Competitive)	Human	S, P	0.1～10μg/ml	RD195023100
		High Sensitivity (Sandwich)	Human	S, P (E, C, H), U, CSF	1～150 ng/ml	RD191023100
			Mouse	S, CM	0.25～8 ng/ml	RD293023100R
	Angiopoietin-Like Protein 3		Mouse/Rat	S, P, CS	0.016～1 ng/ml	RAG011R
	Angiopoietin-Like Protein 6		Human	S, P, CS	1.56～100 ng/ml	RAG001R
C	Chemerin		Human	S, P	0.25～8 ng/ml	RD191136200R
F	FGF-19		Human	S, P	12.5～800 pg/ml	RD191107200R
	FGF-21		Human	S, P (E, C, H)	30～1,920 pg/ml	RD191108200R
			Mouse/Rat	S	40～2,560 pg/ml	RD291108200R
I	Insulin		Human	S	5.1～250μIU/ml	RIS006R
		High Sensitive	Mouse	S, P	0.2～7 ng/ml	RAI005R
		Ultra Sensitive	Mouse	S, P	0.025～1.5 ng/ml	RAI007R
		Wide Range	Mouse	S, P	1～50 ng/ml	RAI003R
		(1x96 wells)	Mouse/Rat	S, P	0.08～10 ng/ml	RA19004R
		(5x96 wells)	Mouse/Rat	S, P	0.08～10 ng/ml	RA19004-480R
		High Sensitive	Rat	S, P	0.2～7 ng/ml	RAI006R
		Ultra Sensitive	Rat	S, P	0.025～1.5 ng/ml	RAI008R
		Wide Range	Rat	S, P	1～50 ng/ml	RAI004R
			Rat	S, P	0.156～10 ng/ml	RTC018R
	IL-6		Human	S, P, U, CSF, BALF, AF	1.5～80 pg/ml	RD194015200R
			Mouse	S, P (E, C), CS	31.3～2,000 pg/ml	RAF071R
			Rat	S, CS	31～2,000 pg/ml	RAF072R
	IL-33		Human	S, P (E, C), CS	7.8～500 pg/ml	RAF064R
	Irisin		Human	S, P (E, H), CS	0.001～5 μg/ml	RAG018R
L	Lecithin-Cholesterol Acyltransferase		Human	S, P (E, C), CSF	2.5～160 ng/ml	RD191122200R
	Leptin	Clinical Range	Human	S, P	1～50 ng/ml	RD191001100
			Mouse/Rat	S, P, CM	100～4,000 pg/ml	RD291001200R
	Leptin Receptor		Human	S, P (E, C)	2～100 ng/ml	RD194002100
	Lipocalin 2/NGAL		Human	S, P (E), U, Stool	0.3～10 ng/ml	RD191102200R
M	Monocyte Chemotactic Protein-1	Sensitive	Human	S, P (E, H), CS	15.6～1,000 pg/ml	RAF081R
			Mouse	S, CM	15.6～1,000 pg/ml	RAF080R
O	Obestatin		Mouse/Rat	P	156.2～20,000 pg/ml	RA19014R
	Omentin-1		Human	S, P	2～64 ng/ml	RD191100200R
P	PCSK9		Human	S, P	125～4,000 pg/ml	RD191473200R
	PEDF		Human	S, P (E, C, H)	0.15～6 ng/ml	RD191114200R
	Progranulin		Human	S, P	75～2500 pg/ml	RMEE103R
			Mouse	S, CS	0.125～8 ng/ml	RAG014R
			Rat	S, CS	0.063～4 ng/ml	RAG015R
R	RBP4		Human	S, P, U, CS	0.001～5μg/ml	RAG005R
		High Sensitivity	Human	S, P, U, CS	0.39～25 ng/ml	RAG021R
			Mouse/Rat	S, U, CS	0.188～12 ng/ml	RAG007R
	Resistin		Human	S, P	1～50 ng/ml	RD191016100
S	S100A12		Human	S, BALF, Stool	0.063～4 ng/ml	RD191221200R
	sRAGE		Human	S, P	50～3200 pg/ml	RD191116200R
T	TNF-α		Human	S, P, U, CS	7.8～500 pg/ml	RAF128R
			Mouse	S, P, CS	31.3～2,000 pg/ml	RAF129R
			Rat	S, CS	39.1～2,500 pg/ml	RAF130R
	TNF-α, Total		Human	S, P, CS	23～1,500 pg/ml	RAF132R
V	Visfatin (NAMPT)		Human	S	0.125～8 ng/ml	RAG004R
		IntraCellular	Human	Cell lysate	0.063～16 ng/ml	RAG008R

目次に戻る

使用文献：Obesitology Publications

• Teunissen CE, et al., Alzheimers Dement. (Amst)., 2:86～94(2016).
  "Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics."
• Burak MF, et al., Sci. Transl. Med., 7(319):319ra205(2015).
  "Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes."
• Tso AW, et al., Diabetes Care., 30(10):2667～2672(2007).
  "Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort."
Epub 2007 Jul 9.
• Xu A, et al., Circulation., 115(12):1537～1543(2007).
  "Circulating adipocytefatty acid binding protein levels predict of the metabolic syndrome: a 5-year prospective study."
• Ahola S, et al., EMBO Mol. Med., (2016).
  "Modified Atkins diet induces subacute selective raggedred～ fiber lysis in mitochondrial myopathy patients."
• von Holstein-Rathlou S, et al., Cell Metab., 23(2):335～343(2016).
  "FGF21 Mediates Endocrine Control of Simple Sugar Intake and Sweet Taste Preference by the Liver."
• Laeger T, et al., J. Clin. Invest., 124(9):3913～3922(2014).
  "FGF21 is an endocrine signal of protein restriction."
• Mutamen A, et al., J. Hepatol., 60(1):183～190(2014).
  "Serum FGF21 increases with hepatic fat accumulation in pediatric onset intestinal failure."
• Bookout AL, et al., Nat. Med., 19(9):1147～1152(2013).
  "FGF21 regulates metabolism and circadian behavior by acting on the nervous system."
• Owen BM, et al., Nat. Med., 19(9):1153～1156(2013).
  "FGF21 contributes to neuroendocrine control of female reproduction."
• Szewczyk-Golec K, et al., Oxid. Med. Cell Longev., 20178494107(2017). doi: 10.1155/2017/ 8494107
  "Supplementation Lowers Oxidative Stress and Regulates Adipokines in Obese Patients on a Calorie- Restricted Diet."
• van Gemert WA, et al., Endocr. Relat. Cancer., pii: ERC-16～0490(2017). doi: 10.1530/ERC-16-490
  "Association between changes in fat distribution and biomarkers for breast cancer."
• Luque-Ramirez M, et al., Hum. Reprod., 28(7):1908～1918(2013).
  "Sexual dimorphism in adipose tissue function as evidenced by circulating adipokine concentrations in the fasting state and after an oral glucose challenge."
von Eynatten M, et al., Diabetes., 58(9):2093～2099(2009).
"Urinary adiponectin excretion: a vascular damage in type 2 diabetes."
• Hernandez EA, et al., J. Clin. Invest., 127(2):695～708(2017). doi: 10.1172/JCI89444.
  "Acute dietary fat intake initiates alterations in energy metabolism and insulin resistance."
• Aleksandrova K, et al., Cancer Res., 76 (13):3862～3871(2016).
  "Circulating Omentin as a Novel Biomarker for Colorectal Cancer Risk: Data from the EPIC-Potsdam Cohort Study."
• Wittenbecher C, et al., Diabetes Care., 36(6):e79～80(2016).
  "Omentin-1, Adiponectin, and the Risk of Developing Type 2 Diabetes."
• Kataoka Y, et al., J. Am. Coll. Cardiol., 2014 Apr 11.
  "Omentin prevents myocardial ischemic injury through AMPKand Akt-dependent mechanisms."
• Sabry JH, et al., International J. Recent Scientific Research., 8(3):15862～15866(2017).
  "Serum pigment epithelium derived factor as a new marker in the metabolic syndrome."
• Hui E, et al., J. Clin. Endocrinol. Metab., 99(11):E2169～2177(2014).
  "Elevated circulating pigment epitheliumderived factor predicts the progression of diabetic nephropathy in patients with type 2 diabetes. "
• Famulla S, et al., Int. J. Obes (Lond)., 35(6):762～772(2011).
  "Pigment epitheliumderived factor (PEDF) is one of the most abundant proteins secreted by human adipocytes and induces insulin resistance and inflammatory signaling in muscle and fat cells."
• Hung CS, et al., PLoS One., 9(5):e97710(2014).
  "Evaluation of circulating adipokines and abdominal obesity as predictors of significant myocardial ischemia using gated single-photon emission computed tomography."
• Kohara M, et al., PLoS One., 12(6):e0178971(2017). doi: 10.1371/journal. pone.0178971
  "Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease."
• Sahebkar A, et al., Atherosclerosis., 230(1):110～120(2013).
  "Fibrate therapy and circulating adiponectin concentrations: a systematic review and meta-analysis of randomized placebocontrolled trials."
• Kadoglou NP, et al., Atherosclerosis., 235(2):606～612(2014).
  "The relationship of novel adipokines, RBP4 and omentin-1, with carotid atherosclerosis severity and vulnerability."

目次に戻る